Tabletting: Expert Views - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tabletting: Expert Views
Pharmaceutical Technology Europe brings together suppliers of tabletting equipment and excipients to discuss the challenges, innovations and latest trends in the tabletting industry.


Pharmaceutical Technology Europe
Volume 4, Issue 23

Q. What are the key drivers for change in the tabletting industry?

Chris Prideaux: There are many changes affecting the tabletting industry — many of which stem from those taking place in the pharma industry as a whole. The biggest drivers for change are the number of blockbusters coming off patent, and the inexorable growth of generic drug producers and contract manufactures. Both factors place an immediate demand on suppliers of manufacturing equipment for systems offering better speed of response and better value for money. The drive to optimise growth opportunities in developing markets is also leading to greater globalisation. The relocation of facilities away from traditionally high-cost developed markets to lower-cost developing markets means that suppliers of tabletting machines and other pharma manufacturing equipment must be able to meet the needs of these markets and provide increasing levels of support.

Dale Natoli: I think the main focus of the tabletting industry at the moment is on quality, and boosting productivity and manufacturing efficiency. From a tablet compression tooling standpoint, regulatory affairs are making a stronger presence in medium and large-scale operations with regards to more stringent process controls to ensure tablet quality.

Sophie Chesnoy: Looking at the tabletting industry from the point of view of an excipient supplier, the main drivers for change will be the development of new excipients for solid dosage forms that enable better control over physical properties, ultimately improving the quality of the final product. In particular, tabletting manufacturers' needs for improved powder flowability, compressibility and lubrication are key in driving excipient innovation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here